ACTUATE THERAPEUTICS, INC. (ACTU)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$8.1M
Cash & Equivalents
$5.0M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$29M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-12-31 Phase2 Readout —

Active Clinical Trials (4)

NCT #TitlePhaseStatusEnrollment
NCT05077800 FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer PHASE2 Active Not Recruiting 70
NCT05010629 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma PHASE2 Active Not Recruiting 35
NCT03678883 9-ING-41 in Patients With Advanced Cancers PHASE2 Active Not Recruiting 350
NCT06896188 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLE... PHASE1 Recruiting 12

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ACTU.

SEC EDGAR Filings

All SEC filings for ACTUATE THERAPEUTICS, INC. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.